Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00973141 · ClinicalTrials.gov registry record · Phase 2
A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain
A Phase 2 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Terminated
- Registry status
- Phase 2
- Development phase
- 467
- Enrollment target
NCT00973141 is a Phase 2 study that was terminated before completion, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 467 participants.
The verdict
NCT00973141, a Phase 2 study, was terminated before completion, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 467 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and effectiveness of different doses of JNJ-42160443 with placebo in the treatment of chronic, moderate to severe knee or hip pain in patients with a diagnosis of osteoarthritis.
Interventions
- DRUG Placebo
- DRUG JNJ-42160443
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 467 participants |
| Start Date | 2009-09-16 |
| Est. Completion | 2011-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00973141
The ClinicalTrials.gov registry entry for NCT00973141 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 467 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00973141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00973141 about?
NCT00973141 is a clinical study titled "A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain". The purpose of this study is to compare the safety and effectiveness of different doses of JNJ-42160443 with placebo in the treatment of chronic, moderate to severe knee or hip pain in patients with a diagnosis of osteoarthritis.
What is the current status of trial NCT00973141?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 467 participants. The study started on 2009-09-16. Estimated completion is 2011-06-30.
What interventions are being tested in trial NCT00973141?
The interventions under investigation include: Placebo (DRUG), JNJ-42160443 (DRUG).
Who is sponsoring clinical trial NCT00973141?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.